SureNano Science Advances GEP-44 Toward Clinical Trials with IND-Enabling Program

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has initiated a Good Laboratory Practice (GLP) toxicology and pharmacology program for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. This FDA-aligned program is a critical step toward an Investigational New Drug (IND) application and eventual first-in-human clinical trials. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, with preclinical results positioning GEP-44 head-to-head with established therapies such as Ozempic, Mounjaro, and Wegovy.

The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes. SureNano, a Canadian life sciences company, is positioning itself as an agile entrant in the next-generation GLP-1 landscape, having secured licensing rights to the GEP-44 compound developed by Syracuse University. The company is also exploring acquisition or licensing of Ibogaine-related intellectual property for potential mental health and addiction treatments, following its acquisition of GlucaPharm.

The global GLP-1 receptor agonist market is projected to reach between $100 billion and $200 billion by 2030, according to J.P. Morgan estimates, with approximately 25 million patients in the United States alone expected to use GLP-1 therapies by that time. SureNano's transition toward a pharmaceutical-focused model aligns with this rapid market expansion. For the latest news and updates on SureNano, visit the company's newsroom at https://ibn.fm/SURNF.

Forward-looking information in this release involves risks and uncertainties, including market prices, study and trial results, continued availability of capital and financing, and general economic conditions. The company cautions that actual performance may differ materially from expectations. Readers should not place undue reliance on forward-looking statements, which are qualified in their entirety by this cautionary statement. The information is current as of the date of release and subject to change.